Form 144 Replimune Group Inc. For: 20 November By Investing.com
This article from Investing.com announces the filing of Form 144 by Replimune Group Inc. on November 20. Form 144 is a notice of the intent to sell restricted securities. The article provides this key update regarding the company's stock activity.
Replimune CMO Konstantinos Xynos sells $349,876 in stock for taxes
Replimune Group, Inc.'s Chief Medical Officer, Konstantinos Xynos, sold 16,198 shares of company stock for $349,876 on November 16, 2026, to cover tax withholding obligations. This "sell to cover" transaction was not discretionary and occurred as Replimune's stock, despite a significant annual return, is considered overvalued by some analysts. The company recently reported a smaller-than-expected fiscal Q2 loss while initiating the commercial rollout of its new product, TUDRIQEV, though it has yet to generate revenue from it.
Replimune CMO Konstantinos Xynos Sells 16,198 Shares to Cover RSU Tax Withholding
Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc., sold 16,198 shares of common stock on November 16, 2026, to fulfill tax withholding obligations from vested Restricted Stock Units (RSUs). The sale was a non-discretionary transaction executed at an average price of $21.60 per share. Following the transaction, Xynos directly holds 208,017 shares of Replimune common stock.
Replimune CEO Sold Shares Worth Over $1M
Sushil Patel, CEO of Replimune Group, Inc., sold 49,026 shares worth over $1 million on November 16, 2026. This sale was non-discretionary, executed to cover tax withholding obligations from restricted stock units under an irrevocable "sell-to-cover" provision. Following the transaction, Patel directly owns 659,125 shares.
Replimune Group CFO Emily Hill sells $317,714 in stock
Emily Hill, CFO of Replimune Group Inc., sold 14,709 shares of common stock for $317,714 on November 16, 2026. This sale was to cover tax withholding obligations from vested Restricted Stock Units, not a discretionary decision. The company's stock has since declined nearly 10% in the past week, though it has delivered a 120% return over the past year.
Replimune chief accounting officer sells $46,396 in stock
Andrew Schwendenman, Chief Accounting Officer at Replimune Group, Inc. (NASDAQ:REPL), sold 2,148 shares of the company’s common stock for $46,396 to cover tax withholding obligations. This "sell to cover" transaction was not discretionary and occurred as Replimune's stock declined 9.9% in the past week but still boasts a 120% return over the past year. The company recently reported a smaller-than-expected fiscal second-quarter loss, despite no revenue from its newly launched product, TUDRIQEV.
Form 144 REPLIMUNE GROUP For: 18 November By Investing.com
This article announces the filing of Form 144 for REPLIMUNE GROUP on November 18, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief notice from Investing.com is primarily an informational headline about the filing.
Replimune (REPL) director reports 34,500 shares for sale following a cash-paid stock option exercise.
Replimune Group, Inc. (REPL) director Veleka Peeples-Dyer has reported her intention to sell 34,500 common shares, valued at approximately $693,544.50, with an approximate sale date of November 17, 2026. These shares were acquired through a cash-paid stock option exercise on the same date. The filing also details her previous sales of 10,000 shares on October 30, 2026, and 12,000 shares on October 28, 2026.
REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
Replimune Group (REPL) stock has surged 80% over the past month, driven by the commercial launch of its cancer therapy, Tudriqev, and strong investor confidence. The FDA granted accelerated approval to Tudriqev in August 2026 for advanced cutaneous melanoma, with encouraging early market adoption. The company also reported better-than-expected earnings and is advancing other pipeline candidates like RP2, which offers additional growth opportunities in various cancer indications.
Replimune Group Stock Short Interest Rises to 36.13%
Replimune Group (REPL) saw its short interest rise to 36.13% of the float as of October 30th, an increase of 6.23% from October 15th, according to new data from Benzinga. It would take an estimated 8.31 days for short sellers to cover their positions at current trading volumes. The article also details recent hedge fund activity, with 117 institutions adding and 120 decreasing shares, and highlights insider selling activity totaling 14 sales and no purchases in the last 6 months.
More than 4 million Replimune (REPL) shares sit in State Street’s reported stake.
State Street Corporation has reported beneficial ownership of 4,174,260 common shares, representing 4.4% of Replimune Group, Inc. (REPL). This disclosure was made in a Schedule 13G SEC filing, indicating State Street's shared voting power over 4,080,714 shares and shared dispositive power over all 4,174,260 shares. The event date for this ownership report was September 30, 2026.
A director proposes selling 5,200 Replimune (REPL) shares through Morgan Stanley Smith Barney.
Replimune Group, Inc. (REPL) director Joseph P. Slattery has proposed selling 5,200 common shares with an aggregate market value of $113,360. The shares were acquired through exercise on July 20, 2018, with the approximate sale date set for November 9, 2026, through Morgan Stanley Smith Barney LLC. This information was disclosed in a Form 144 SEC filing.
Form 144 REPLIMUNE GROUP For: 9 November By Investing.com
This article from Investing.com announces the filing of Form 144 for REPLIMUNE GROUP on November 9, 2026. Form 144 is a notice filed with the SEC by an affiliate of a company proposing to sell restricted securities without registration. The article provides minimal details beyond the filing announcement.
Goldman Sachs reports 3.1M Replimune (REPL) shares, with voting power shared.
Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have reported a beneficial ownership of 3,115,243 shares, or a 3.3% stake, in Replimune Group, Inc. (REPL). Both entities share voting power over 3,115,199 shares and dispositive power over 3,115,243 shares, with no sole voting or dispositive power reported. This disclosure is made through an amended SCHEDULE 13G/A filing with the SEC, indicating a passive investment.
Replimune Group stock hits 52-week high at 21.27 USD By Investing.com
Replimune Group Inc. (REPL) stock hit a new 52-week high of $21.27, reflecting a significant 155.48% increase over the past year and a 482% gain in the last six months. Despite this surge, InvestingPro suggests the stock is in overbought territory and may be overvalued. The company recently reported a smaller-than-expected fiscal second-quarter loss and launched its first approved product, TUDRIQEV, though it recorded no revenue from it yet.
Technical Reactions to REPL Trends in Macro Strategies
This report provides a technical analysis of Replimune Group Inc. (NASDAQ: REPL), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for near-term, mid-term, and long-term horizons.
Replimune Group stock hits 52-week high at 21.27 USD By Investing.com
Replimune Group (REPL) stock reached a new 52-week high of $21.27, demonstrating a significant 155.48% increase over the past year and a 482% gain in the last six months. While analysts maintain a consensus "Buy" rating, InvestingPro Tips suggest the stock may be overbought and overvalued. The company also recently reported a smaller-than-expected fiscal second-quarter loss and launched its first approved product, TUDRIQEV, despite reporting no revenue for the period.
What Just Happened With Replimune Group (REPL)?
Replimune Group (REPL) recently reported its Q2 and H1 results, showing narrowed net losses, which followed a significant surge in its share price over the past 30 and 90 days, and a 1-year return of 135.53%. Despite a narrative suggesting the stock is 3% overvalued at $20.02 against a fair value of $19.50, Simply Wall St's DCF model indicates the stock is deeply undervalued, trading about 85% below an estimated future cash flow value of $131.38, highlighting differing views on its valuation post-FDA approval and analyst upgrades.
Jim Cramer Recommends FedEx: ‘Very Nice Move Off The Bottom’
Jim Cramer endorsed buying FedEx Freight Holding Company (NYSE: FDXF) on CNBC's "Mad Money Lightning Round," citing its strong recovery and better-than-expected third-quarter financial results. He also provided recommendations on other stocks, suggesting Replimune Group (NASDAQ: REPL) as a speculative play, advising sticking with Tesla for self-driving exposure over Aurora Innovation, and highlighting Celestica Inc. (NYSE: CLS) as a solid company likely to bounce first. Cramer also mentioned that the upcoming election would be a "clearing event" for Sterling Infrastructure (NASDAQ: STRL).
Replimune director Kapil Dhingra sells $408,500 in stock By Investing.com
Kapil Dhingra, a director at Replimune Group, Inc. (NASDAQ:REPL), sold 21,500 shares of company stock worth approximately $408,500 to cover tax obligations from stock option exercises. The sale occurred while the stock was trading near its 52-week high, after a significant 582% surge in six months. Concurrently, Dhingra also exercised non-qualified stock options to acquire 43,169 shares for $75,545.
Form 4 Replimune Group Inc: Kapil Dhingra (Director) For: 2 November
This article reports on a Form 4 filing for Replimune Group Inc, indicating activity by Director Kapil Dhingra on November 2nd. Form 4 filings are used to disclose transactions by company insiders, providing transparency into their stock ownership. The information is relevant for investors tracking insider sentiment and potential future movements in Replimune Group Inc's stock (REPL).
Replimune Group, Inc. (REPL) options chain
This article from Yahoo Finance provides the options chain for Replimune Group, Inc. (REPL) as of November 3, 2026. It lists both call and put options with various strike prices and details such as last trade date, last price, volume, and open interest. The data is delayed by 15 minutes, and the stock was trading at $20.65, up 5.95% at the close.
Is Replimune Group (REPL) Above Fair Value After A 119% Jump?
Replimune Group (REPL) has experienced a significant 119% share price increase year-to-date, prompting questions about its valuation relative to its book value. The company's P/B ratio of 9.0x is considerably higher than the biotech sector average, indicating it may be overvalued based on this metric. While early commercial success of TUDRIQEV and expanded guideline inclusion could support future cash generation, analysts hold mixed views on whether the current market price is justified.
Form 144 Replimune Group Inc. For: 2 November By Investing.com
This article announces the filing of Form 144 for Replimune Group Inc. on November 2, 2026. Form 144 is a notice of the intent to sell restricted securities, typically filed by insiders. The article indicates a 10.68% increase in REPL, the stock symbol for Replimune Group Inc.
After selling 12,000 shares, Replimune (REPL) director proposes selling 10,000 more.
Replimune Group, Inc. director Veleka Peeples-Dyer has proposed selling an additional 10,000 common shares, valued at $167,232.00, with an approximate sale date of October 30, 2026. This proposed sale follows a previous sale of 12,000 common shares on October 28, 2026, which generated $154,744.80. The notice also indicates a simultaneous stock option exercise for 10,000 shares on October 30, 2026.
Leerink Partners maintains Replimune Group at Outperform, raises price target to $31 from $19
Leerink Partners has reiterated its "Outperform" rating for Replimune Group and increased its price target from $19 to $31, representing a 63.2% hike. This new price target suggests a 93.0% upside from the stock's closing price of $16.06 on October 28. Investors can find more detailed analyst ratings and price target data for Replimune Group on the Forecasts tab of TradingView.
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $20.14, Implies 54% Upside
Analysts have increased the average 12-month price target for Replimune Group, Inc. (REPL) stock to $20.14, up from $19.43, implying a potential upside of approximately 54% based on the recent closing price. The consensus rating from 8 covering analysts remains a "Buy," with all analysts recommending a Buy.
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Replimune reported its fiscal second quarter 2027 financial results, highlighting a net loss of $65.3 million. The company also provided a corporate update, focusing on its financial position with cash, cash equivalents, and marketable securities totaling $515.6 million. This update reflects the company's operational status and financial health.
All eyes on Replimune earnings after melanoma drug launch
Replimune Group Inc. is set to report its first quarterly earnings that may include commercial revenue following the FDA approval of its melanoma therapy, Tudriqev, in August. Analysts anticipate a loss of 75 cents per share on $1 million in revenue, a significant milestone as the company transitions to a commercial stage. Investors will closely monitor the launch trajectory of Tudriqev, competitive dynamics with Iovance Biotherapeutics' Amtagvi, and operational execution metrics such as reimbursement negotiations and manufacturing.
Replimune Group Q2 2027 Earnings Call Transcript
Replimune Group (NASDAQ: REPL) reported its second-quarter fiscal 2027 financial results, marking the commercial launch of its first product, Tudrakev, for melanoma. The company reported strong early traction, with over 70% of initial target accounts engaged and more than 15 institutions prescribing Tudrakev within three weeks. Replimune highlighted the broad label, rapid NCCN guideline inclusion, and swift insurance coverage as key factors for this early success, emphasizing the unmet patient need.
Replimune Group 3Q 2026: Revenue $0 Net loss $57.1M, EPS ($0.54) — 10-Q Summary
Replimune Group reported no product revenue in the third quarter of 2026, as commercial sales of TUDRIQEV only began in October. The company's net loss narrowed to $57.1 million from $83.1 million a year prior, with diluted loss per share at $0.54. TUDRIQEV received accelerated FDA approval in August 2026, and its U.S. commercial availability began in early October, with promising response rates in melanoma patients.
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Replimune Group, Inc. announced its fiscal second quarter 2027 financial results and a corporate update, highlighting the commercial availability of TUDRIQEV for advanced melanoma. The company reported $307.8 million in cash and cash equivalents, a net loss of $57.1 million for the quarter, and positive early launch engagement for TUDRIQEV. Replimune also provided updates on its ongoing clinical trials for TUDRIQEV and RP2.
Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss
Replimune reported a net loss of $57.1 million for the fiscal second quarter ended September 30, 2026, a significant improvement from $83.1 million a year prior. The company had $307.8 million in cash and cash equivalents and announced that TUDRIQEV is now commercially available in the U.S. for advanced melanoma. Clinical studies for TUDRIQEV and RP2 are actively enrolling, with TUDRIQEV also included in NCCN Clinical Practice Guidelines.
Replimune Group, Inc. (REPL) Tops Q2 EPS by 21c
Replimune Group, Inc. (NASDAQ: REPL) reported its Q2 EPS, which significantly beat analyst estimates. The company posted an EPS of ($0.54), outperforming the analyst forecast of ($0.75) by $0.21. Following the announcement, REPL's stock price saw a notable increase.
Replimune Beats On A Shrinking Loss, But The TUDRIQEV Launch Is Still Measured In Accounts, Not Revenue
Replimune Group (NASDAQ: REPL) reported a fiscal second-quarter loss of $0.54 per share, beating consensus estimates, with a net loss that narrowed to $57.1 million from $83.1 million year over year. The company recorded no revenue as its oncolytic therapy, TUDRIQEV, launched after the quarter closed. While the early launch indicators are encouraging in terms of account adoption and payer coverage, the market is awaiting revenue guidance and patient disclosure to fully credit the launch.
A melanoma treatment reached patients Oct. 6. More than 15 institutions have prescribed it.
Replimune Group (REPL) reported a narrowed fiscal second-quarter net loss of $57.1 million and provided a corporate update, highlighting the commercial launch of its melanoma treatment, TUDRIQEV. The treatment was first delivered to patients on October 6, 2026, and has been prescribed by over 15 institutions for adults with unresectable advanced cutaneous melanoma. The company also confirmed active enrollment in its IGNYTE-3 confirmatory trial and RP2 REVEAL trial, and expects its current cash to fund operations for more than twelve months.
Replimune Group stock hits 52-week high at 16.39 USD
Replimune Group Inc. (REPL) stock reached a 52-week high at $16.39, reflecting a 55.14% increase over the past year and a dramatic 408% return over six months. Despite this surge, InvestingPro analysis suggests the stock might be overvalued, with analyst targets ranging from $14 to $24. The company also reported a smaller-than-expected fiscal second-quarter loss of $0.54 per share, though it missed revenue forecasts and just began commercial shipments of its first approved product, TUDRIQEV.
Replimune Group, Inc. Estimates – NASDAQ:REPL
This article provides a financial overview of Replimune Group, Inc. (NASDAQ: REPL) on TradingView. It offers access to reported financial data and analyst estimates for the income statement, balance sheet, cash flow statement, and various valuation metrics, allowing users to compare actual results with estimates and visualize trends.
REPL Q2'26 Earnings: revenue estimate is 0 USD
Replimune Group, Inc. (REPL) is scheduled to announce its Q2'26 earnings on October 29. The company's revenue estimate for Q2'26 is 0 USD, with an anticipated EPS of (0.78) USD. This information is provided ahead of the official disclosure expected at 8:00 AM ET (12:00 PM UTC).
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
Replimune Group, Inc. (NASDAQ: REPL) announced it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET. The call will discuss its financial results and provide a corporate update for the fiscal second quarter ended September 30, 2026. The company, a commercial stage biotechnology firm, specializes in developing novel oncolytic immunotherapies.
Replimune faces November 5 results: Replimune stock has USD 1.1 billion value
Replimune Group is expected to release its Q2 fiscal 2027 earnings on November 5, 2026, with an anticipated loss of $0.7840 per share and revenue of $1.00 million. The clinical-stage biotechnology company, valued at $1.1 billion, recently saw its Nasdaq stock close at $10.86, 33.50% below its yearly high. Investors are closely watching these reports, especially after the recent commercial availability of its TUDRIQEV treatment for advanced melanoma in the US.
Replimune Group Inc (7R8.DU) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Replimune Group Inc (7R8.DU) stock, including its current price, historical data, and key financial metrics. The stock is currently trading at 9.97 EUR, up 3.30%, and shows significant year-to-date and 1-year returns. The article also presents performance comparisons against the S&P 500 benchmark.
Brokerages set USD 12.00 target for Replimune stock
Brokerages have set an average target of USD 12.00 for Replimune stock, which is 1.52 percent above its recent Nasdaq price. The company's next earnings are estimated for November 5, 2026, with forecasts predicting a loss of USD 0.7840 per share. Replimune, with a market capitalization of USD 1.1 billion, focuses on engineered HSV-1 viruses to treat tumors.
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
Replimune received accelerated FDA approval for its first commercial drug, Tudriqev, for advanced cutaneous melanoma. While this marks a significant milestone, the company faces a cash crunch, with current capital expected to last only until Q1 2027, before confirmatory trial data is fully available in 2030. Analysts have raised price targets and maintained positive ratings, anticipating strong commercial potential for Tudriqev despite the financial challenges and the need for further trial validation.
(REPL) Movement as an Input in Quant Signal Sets
This article analyzes Replimune Group Inc. (NASDAQ: REPL), highlighting neutral near and mid-term readings that could moderate a long-term positive bias. It details an exceptional 134.0:1 risk-reward setup targeting a 35.3% gain versus 0.3% risk. The analysis also presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside a multi-timeframe signal analysis.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) and its officers, alleging federal securities law violations. The lawsuit claims that Replimune made false and misleading statements and failed to disclose critical information regarding its Biologics License Application (BLA) for RP1-104. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
Cantor Fitzgerald reiterates Overweight on Replimune Group stock
Cantor Fitzgerald has reiterated its "Overweight" rating on Replimune Group (NASDAQ: REPL) following the launch of its drug Tudriqev for melanoma. Despite a significant stock surge, InvestingPro suggests the shares might be overvalued, noting the company's rapid cash burn for the Tudriqev launch. Analysts, however, see potential for the stock to rise, with price targets up to $24.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false or misleading statements regarding deficiencies in its BLA submission for RP1-104, which failed to address FDA concerns and included data from an early, unplanned analysis. Investors who suffered losses are encouraged to seek lead plaintiff status by October 5, 2026.
Cantor Fitzgerald reiterates Overweight on Replimune Group stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on Replimune Group (NASDAQ:REPL) following the launch of its drug Tudriqev for melanoma treatment. Despite a significant stock surge over the past year, InvestingPro analysis suggests the shares may be overvalued, noting the company's rapid cash burn as it invests in the Tudriqev launch. The article highlights analyst optimism with price targets up to $24 and recent upgrades from other firms like Wedbush and Leerink, driven by positive FDA approvals and advisory committee votes for Tudriqev.
Replimune Group, Inc. (REPL) Options Chain
This article provides the options chain data for Replimune Group, Inc. (REPL) as of October 5, 2026. It includes detailed information for both call and put options, such as strike prices, last trade dates, last prices, and implied volatility. The data shows options with varying strike prices and notes a delay of 15 minutes.